Predictive Oncology (NASDAQ:POAI) Share Price Passes Below 200 Day Moving Average – Should You Sell?

Shares of Predictive Oncology Inc. (NASDAQ:POAI) crossed below its 200-day moving average during trading on Thursday . The stock has a 200-day moving average of $12.30 and traded as low as $5.86. Predictive Oncology shares last traded at $5.90, with a volume of 23,458 shares trading hands.

Analyst Ratings Changes

Separately, Weiss Ratings restated a “sell (e+)” rating on shares of Predictive Oncology in a research report on Wednesday, October 8th. One research analyst has rated the stock with a Sell rating, Based on data from MarketBeat.com, Predictive Oncology has a consensus rating of “Sell”.

Predictive Oncology Trading Up 3.9%

The company has a market capitalization of $20.78 million, a PE ratio of -0.45 and a beta of 1.26. The firm has a 50 day simple moving average of $10.05 and a two-hundred day simple moving average of $12.23.

Predictive Oncology (NASDAQ:POAI) last posted its quarterly earnings data on Friday, November 14th. The medical instruments supplier reported ($4.52) earnings per share for the quarter, missing analysts’ consensus estimates of ($1.35) by ($3.17). The firm had revenue of $0.00 million during the quarter, compared to analysts’ expectations of $1.50 million. Predictive Oncology had a negative net margin of 5,065.23% and a negative return on equity of 732.73%. Research analysts expect that Predictive Oncology Inc. will post -2.08 earnings per share for the current fiscal year.

About Predictive Oncology

Predictive Oncology Inc operates as a science-driven company on the oncology drug discovery. It provides various solutions for the oncology drug development. The company, through the integration of scientific rigor and machine learning, has developed the ability to advance molecules into medicine by introducing human diversity earlier into the discovery process with the pairing of artificial intelligence and the biobank of approximately 150K tumor samples.